Xlife Sciences: First Valuation Report confirms substancial

Xlife Sciences: First Valuation Report confirms substancial potential of the project portfolio and assumes CHF 574 million in the most conservative scenario Seite 1

09.05.2022 - Xlife Sciences AG / Key word(s): Miscellaneous Xlife Sciences: First Valuation Report confirms substancial potential of the project portfolio and assumes CHF 574 million in the most conservative scenario 09-May-2022 / 07:00 CET/CEST Release of an ... Seite 1

Related Keywords

Quadira Biosciences , Oliverr Baumann , Xlife Sciences , Evaluation Report , Veraxa Biotech , Cylad Experts ,

© 2025 Vimarsana